Local therapy treatment conditions for oligometastatic non-small cell lung cancer
Standard treatments for patients with metastatic non-small cell lung cancer (NSCLC) include palliative chemotherapy and radiotherapy, but with limited survival rates. With the development of improved immunotherapy and targeted therapy, NSCLC prognoses have significantly improved. In recent years, th...
Main Authors: | Suli Zhang, Qian Sun, Feng Cai, Hui Li, Yufu Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1028132/full |
Similar Items
-
Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients
by: Ming-Wei Ma, et al.
Published: (2022-10-01) -
Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT
by: Meritxell Molla, et al.
Published: (2021-05-01) -
SABR for oligometastatic renal cell carcinoma
by: Chang David, et al.
Published: (2024-03-01) -
Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
by: David L. Billing, et al.
Published: (2021-11-01) -
Classifying Oligometastatic Non-Small Cell Lung Cancer
by: Alisa N. Blumenthaler, et al.
Published: (2021-09-01)